CANadian Adaptive DBS TriAl (CANADA)
Primary Purpose
Parkinson Disease
Status
Not yet recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Adaptive DBS
Continuous DBS
Sponsored by
About this trial
This is an interventional treatment trial for Parkinson Disease
Eligibility Criteria
Inclusion Criteria:
- PD treated with bilateral STN DBS using Medtronic lead
- Able to provide informed consent and comply with study protocol
- Need to replace the implantable pulse generator (IPG) due to battery end of life
- Presence of disabling gait and/or balance and/or speech issues, as clinically judged by the PI and the patient
- Evidence that these disabling gait and/or balance and/or speech issues are worsened by DBS, i.e. they improve after turning DBS off.
- Use of contact 1 and/or 2 on one hemisphere and/or 9 and/or 10 on the other one
- Good LFP signal (assessable only after IPG replacement with Percept) in at least one hemisphere
Exclusion Criteria:
- Previous DBS surgery without Medtronic products
- Potential use of any therapeutic stimulation configuration (such as bipolar) during the study which will prevent the use of aDBS
- Presence of any other disorders potentially impacting the outcome measures (e.g. orthopaedic issues)
- Medically unstable
- Severe non-motor problems, such as depression, dementia, etc.
Sites / Locations
- Movement Disorders Centre - Toronto Western Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Active Comparator
Arm Label
Continuous DBS
Adaptive DBS
Arm Description
Outcomes
Primary Outcome Measures
Change in Activities of Daily Living using the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II
Unified Parkinson's Disease Rating Scale (MDS-UPDRS) II: Motor Aspects of Experiences of Daily Living (M-EDL), range 0-52. Lower scores reflect better motor experience.
Change in Quality of Life (QoL) using Parkinson's Disease Questionnaire (PDQ39)
Parkinson's Disease Questionnaire (PDQ39): 8 dimensions, 5-point ordinal scoring system, each dimension total score range from 0 to 100. Lower scores reflect better QoL.
Change in Gait using the Zeno Walkway by Protokinetics
Gait analysis (off and on medication) using the Zeno Walkway by Protokinetics.
Change in Speech Quality using the Praat software (Phonetic Sciences)
Phonetic speech analysis (off and on medication) using the Praat software (Phonetic Sciences, Amsterdam, The Netherlands). Increased phonation reflects better speech quality.
Secondary Outcome Measures
Change in Motor Outcomes (adaptive DBS vs continuous DBS arms) using Unified Parkinson's Disease Rating Scale part III (motor examination)
Unified Parkinson's Disease Rating Scale motor examination (MDS-UPDRS III) score, range 0-132. Lower scores reflect less motor impairment.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05402163
Brief Title
CANadian Adaptive DBS TriAl
Acronym
CANADA
Official Title
Adaptive/Closed Loop vs. Continuous/Open Loop Deep Brain Stimulation of Subthalamic Nucleus: a Two-Phase, Cross-Over, Double-Blind Trial in Patients With Parkinson's Disease
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 1, 2023 (Anticipated)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Toronto
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
Parkinsonian symptoms, such as freezing of gait (FOG) or hypophonia, play a significant role in reducing quality of life for Parkinson disease (PD) patients, and are poorly responsive or can worsen with deep brain stimulation (DBS). Repeated adjustments of stimulation parameters may be beneficial however, continuous DBS (cDBS) does not adapt to the patients' rapidly fluctuating clinical status and does not take into account reliable and consistent state-trait biomarkers. These biomarkers can be recorded by the electrode itself as local field potentials (LFP). These LFPs can be used to guide stimulation output by means of a 'closed loop' or 'adaptive' DBS (aDBS).
This is a pilot, two-phase, double-blinded, cross-over study of chronic Adaptive vs. Continuous STN DBS in patients with PD by using a novel implantable DBS system that can automatically adjust stimulation parameters based on the patient's clinical condition. The study will test the hypothesis that aDBS stimulation will treat motor fluctuations similarly to continuous stimulation but it will be superior to the latter in the treatment of speech, gait impairment and falls.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Continuous DBS
Arm Type
Other
Arm Title
Adaptive DBS
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Adaptive DBS
Intervention Description
aDBS vs cDBS
Intervention Type
Device
Intervention Name(s)
Continuous DBS
Intervention Description
aDBS vs cDBS
Primary Outcome Measure Information:
Title
Change in Activities of Daily Living using the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II
Description
Unified Parkinson's Disease Rating Scale (MDS-UPDRS) II: Motor Aspects of Experiences of Daily Living (M-EDL), range 0-52. Lower scores reflect better motor experience.
Time Frame
Baseline, 5 months after IPG change, 8 months after battery change
Title
Change in Quality of Life (QoL) using Parkinson's Disease Questionnaire (PDQ39)
Description
Parkinson's Disease Questionnaire (PDQ39): 8 dimensions, 5-point ordinal scoring system, each dimension total score range from 0 to 100. Lower scores reflect better QoL.
Time Frame
Baseline, 5 months after IPG change, 8 months after battery change
Title
Change in Gait using the Zeno Walkway by Protokinetics
Description
Gait analysis (off and on medication) using the Zeno Walkway by Protokinetics.
Time Frame
Baseline, 5 months after IPG change, 8 months after battery change
Title
Change in Speech Quality using the Praat software (Phonetic Sciences)
Description
Phonetic speech analysis (off and on medication) using the Praat software (Phonetic Sciences, Amsterdam, The Netherlands). Increased phonation reflects better speech quality.
Time Frame
Baseline, 5 months after IPG change, 8 months after battery change
Secondary Outcome Measure Information:
Title
Change in Motor Outcomes (adaptive DBS vs continuous DBS arms) using Unified Parkinson's Disease Rating Scale part III (motor examination)
Description
Unified Parkinson's Disease Rating Scale motor examination (MDS-UPDRS III) score, range 0-132. Lower scores reflect less motor impairment.
Time Frame
Baseline, 2-5 months after IPG change, 8 months after battery change
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
PD treated with bilateral STN DBS using Medtronic lead
Able to provide informed consent and comply with study protocol
Need to replace the implantable pulse generator (IPG) due to battery end of life
Presence of disabling gait and/or balance and/or speech issues, as clinically judged by the PI and the patient
Evidence that these disabling gait and/or balance and/or speech issues are worsened by DBS, i.e. they improve after turning DBS off.
Use of contact 1 and/or 2 on one hemisphere and/or 9 and/or 10 on the other one
Good LFP signal (assessable only after IPG replacement with Percept) in at least one hemisphere
Exclusion Criteria:
Previous DBS surgery without Medtronic products
Potential use of any therapeutic stimulation configuration (such as bipolar) during the study which will prevent the use of aDBS
Presence of any other disorders potentially impacting the outcome measures (e.g. orthopaedic issues)
Medically unstable
Severe non-motor problems, such as depression, dementia, etc.
Facility Information:
Facility Name
Movement Disorders Centre - Toronto Western Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5T 2S8
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
CANadian Adaptive DBS TriAl
We'll reach out to this number within 24 hrs